honors + affiliations
Recipient, Consultant of the Year, Philadelphia Business Journal Innovation Awards (2013)
Listed, Legal Media Group's Life Sciences "Life Sciences Star" – Transactional (2012–2013)
Former Member, University of Pennsylvania Institutional Review Board
- New York
- U.S. Supreme Court
Fahd M.T. Riaz is a partner in Morgan Lewis's Business and Finance Practice and a member of the Life Sciences Transactions Practice. Mr. Riaz has served as lead counsel for pharmaceutical, biotech, and device companies in a number of large life sciences industry transactions. In addition to providing general corporate and transactional advice, Mr. Riaz's practice focuses particularly on fulfilling the special business and legal needs of public and private life sciences companies as they seek to form joint ventures, partnerships, and other complex collaborations; acquire venture capital financing; and execute mergers, acquisitions, divestitures, and licensing agreements.
Mr. Riaz's clients range from early-stage biotechnology startups to global pharmaceutical companies, as well as medical device and other technology companies. Drawing upon his technical background as a molecular biologist, he advises and provides an assortment of services for these clients in support of a variety of mission-critical undertakings, including the negotiation and structuring of both development and commercial transactions, the facilitation of equity investments, and the navigation of other matters that often accompany such transactions. Related matters include the negotiation and drafting of technical contractual arrangements related to the conducting and outsourcing of drug discovery, development (both clinical and nonclinical; including clinical trial agreements), manufacturing and supply, and marketing. Mr. Riaz serves as outside general counsel for clients and advises boards of directors on disclosure issues, corporate communications policies, and fiduciary duty matters.
Mr. Riaz is admitted to practice in Pennsylvania, Michigan, New York, and Massachusetts and before the U.S. Supreme Court.
- Eisai in its collaboration with CRO, Quintiles, to co-develop six cancer compounds
- Pierrel's purchase of Encorium's U.S. clinical trial business
- Antares Pharma in its license and asset purchase agreement with Ferring
- Profectus BioSciences in the worldwide transfer of Wyeth's therapeutic and prophylatic DNA and vectored vaccine programs for HIV, including NIH contracts providing multimillion dollar funding, as well as HCV, HPV, HSV, and malaria
- Shire Pharmaceuticals in its up to $440 million collaboration with Amicus Therapeutics for the development and commercialization of three therapies for genetic disorders
- EUSA in its acquisition of Collatamp G. Implant product and license of two other products in development
- Solstice in its development and commercialization of Neurobloc in Europe providing €41 million in upfront and milestone payments and development partner
- Velcera in its global licensing agreement with Novartis for its oral mucosal canine promist formulation
- Summers Laboratories in its divestiture of its Lice Asphyxiation Product to Sciele Pharma
- Prism in raising up to $68 million through equity and royalty/revenue monetization
- Solstice in raising $85 million in equity and debt financing
- SANKYO in its up to $320 million collaboration and development with KAI Pharmaceuticals for its delta protein kinase C inhibitor, KAI-9803
- Boston University School of Law, 2002, J.D., Cum Laude
- State University of New York at Buffalo, 1997, B.S., Cum Laude